511 related articles for article (PubMed ID: 20215512)
1. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells.
Lin L; Hutzen B; Zuo M; Ball S; Deangelis S; Foust E; Pandit B; Ihnat MA; Shenoy SS; Kulp S; Li PK; Li C; Fuchs J; Lin J
Cancer Res; 2010 Mar; 70(6):2445-54. PubMed ID: 20215512
[TBL] [Abstract][Full Text] [Related]
2. New curcumin analogues exhibit enhanced growth-suppressive activity and inhibit AKT and signal transducer and activator of transcription 3 phosphorylation in breast and prostate cancer cells.
Lin L; Hutzen B; Ball S; Foust E; Sobo M; Deangelis S; Pandit B; Friedman L; Li C; Li PK; Fuchs J; Lin J
Cancer Sci; 2009 Sep; 100(9):1719-27. PubMed ID: 19558577
[TBL] [Abstract][Full Text] [Related]
3. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice.
Onimoe GI; Liu A; Lin L; Wei CC; Schwartz EB; Bhasin D; Li C; Fuchs JR; Li PK; Houghton P; Termuhlen A; Gross T; Lin J
Invest New Drugs; 2012 Jun; 30(3):916-26. PubMed ID: 21340507
[TBL] [Abstract][Full Text] [Related]
4. Two small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on STAT3 in human rhabdomyosarcoma cells.
Wei CC; Ball S; Lin L; Liu A; Fuchs JR; Li PK; Li C; Lin J
Int J Oncol; 2011 Jan; 38(1):279-85. PubMed ID: 21109950
[TBL] [Abstract][Full Text] [Related]
5. Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines.
Bill MA; Nicholas C; Mace TA; Etter JP; Li C; Schwartz EB; Fuchs JR; Young GS; Lin L; Lin J; He L; Phelps M; Li PK; Lesinski GB
PLoS One; 2012; 7(8):e40724. PubMed ID: 22899991
[TBL] [Abstract][Full Text] [Related]
6. A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells.
Lin L; Deangelis S; Foust E; Fuchs J; Li C; Li PK; Schwartz EB; Lesinski GB; Benson D; Lü J; Hoyt D; Lin J
Mol Cancer; 2010 Aug; 9():217. PubMed ID: 20712901
[TBL] [Abstract][Full Text] [Related]
7. Overcoming chemo/radio-resistance of pancreatic cancer by inhibiting STAT3 signaling.
Wu X; Tang W; Marquez RT; Li K; Highfill CA; He F; Lian J; Lin J; Fuchs JR; Ji M; Li L; Xu L
Oncotarget; 2016 Mar; 7(10):11708-23. PubMed ID: 26887043
[TBL] [Abstract][Full Text] [Related]
8. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells.
Shin DS; Kim HN; Shin KD; Yoon YJ; Kim SJ; Han DC; Kwon BM
Cancer Res; 2009 Jan; 69(1):193-202. PubMed ID: 19118003
[TBL] [Abstract][Full Text] [Related]
9. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells.
Duan Z; Bradner J; Greenberg E; Mazitschek R; Foster R; Mahoney J; Seiden MV
Mol Pharmacol; 2007 Nov; 72(5):1137-45. PubMed ID: 17675586
[TBL] [Abstract][Full Text] [Related]
10. A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.
Lin L; Hutzen B; Li PK; Ball S; Zuo M; DeAngelis S; Foust E; Sobo M; Friedman L; Bhasin D; Cen L; Li C; Lin J
Neoplasia; 2010 Jan; 12(1):39-50. PubMed ID: 20072652
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of head and neck cancer to cisplatin through the use of a novel curcumin analog.
Abuzeid WM; Davis S; Tang AL; Saunders L; Brenner JC; Lin J; Fuchs JR; Light E; Bradford CR; Prince ME; Carey TE
Arch Otolaryngol Head Neck Surg; 2011 May; 137(5):499-507. PubMed ID: 21576562
[TBL] [Abstract][Full Text] [Related]
12. Discovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy.
Zhang W; Guo J; Li S; Ma T; Xu D; Han C; Liu F; Yu W; Kong L
Sci Rep; 2017 Apr; 7():46352. PubMed ID: 28397855
[TBL] [Abstract][Full Text] [Related]
13. Novel thiosemicarbazones regulate the signal transducer and activator of transcription 3 (STAT3) pathway: inhibition of constitutive and interleukin 6-induced activation by iron depletion.
Lui GY; Kovacevic Z; V Menezes S; Kalinowski DS; Merlot AM; Sahni S; Richardson DR
Mol Pharmacol; 2015; 87(3):543-60. PubMed ID: 25561562
[TBL] [Abstract][Full Text] [Related]
14. Small molecule 1'-acetoxychavicol acetate suppresses breast tumor metastasis by regulating the SHP-1/STAT3/MMPs signaling pathway.
Wang J; Zhang L; Chen G; Zhang J; Li Z; Lu W; Liu M; Pang X
Breast Cancer Res Treat; 2014 Nov; 148(2):279-89. PubMed ID: 25301089
[TBL] [Abstract][Full Text] [Related]
15. The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines.
Fossey SL; Bear MD; Lin J; Li C; Schwartz EB; Li PK; Fuchs JR; Fenger J; Kisseberth WC; London CA
BMC Cancer; 2011 Mar; 11():112. PubMed ID: 21443800
[TBL] [Abstract][Full Text] [Related]
16. Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells.
Behera R; Kumar V; Lohite K; Karnik S; Kundu GC
Carcinogenesis; 2010 Feb; 31(2):192-200. PubMed ID: 19926637
[TBL] [Abstract][Full Text] [Related]
17. Curcumin analogue GO-Y030 inhibits STAT3 activity and cell growth in breast and pancreatic carcinomas.
Hutzen B; Friedman L; Sobo M; Lin L; Cen L; De Angelis S; Yamakoshi H; Shibata H; Iwabuchi Y; Lin J
Int J Oncol; 2009 Oct; 35(4):867-72. PubMed ID: 19724924
[TBL] [Abstract][Full Text] [Related]
18. The curcumin analogue hydrazinocurcumin exhibits potent suppressive activity on carcinogenicity of breast cancer cells via STAT3 inhibition.
Wang X; Zhang Y; Zhang X; Tian W; Feng W; Chen T
Int J Oncol; 2012 Apr; 40(4):1189-95. PubMed ID: 22179587
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the JAK2/STAT3 signaling pathway exerts a therapeutic effect on osteosarcoma.
Yan J; Wang Q; Zou K; Wang L; Schwartz EB; Fuchs JR; Zheng Z; Wu J
Mol Med Rep; 2015 Jul; 12(1):498-502. PubMed ID: 25760445
[TBL] [Abstract][Full Text] [Related]
20. IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular cancer cells.
Liu Y; Fuchs J; Li C; Lin J
Cell Cycle; 2010 Sep; 9(17):3423-7. PubMed ID: 20818158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
